A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer

This study is testing a new drug called SDX-7320 combined with eribulin (an existing chemotherapy) for people with triple-negative metastatic breast cancer — a type of breast cancer that does not respond to hormone or HER2 therapies. The goal is to see whether the combination is safe and effective. **You may be eligible if...** - You have been diagnosed with triple-negative metastatic breast cancer - You have had up to 2 prior lines of treatment in the advanced or metastatic setting - You have previously received certain chemotherapy drugs (anthracycline and/or taxane), or your doctor deemed them not appropriate for you - You have signs of metabolic issues, such as a higher HbA1c (blood sugar marker) or BMI of 30 or higher - You are 18 or older with good overall organ function **You may NOT be eligible if...** - You have had 3 or more prior treatments for metastatic disease - You have brain metastases or active brain disease - You have type 1 diabetes or uncontrolled type 2 diabetes - You are currently in another clinical trial - Your BMI is below 18.5 Talk to your doctor to see if this trial is right for you.